1652 related articles for article (PubMed ID: 16461817)
1. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
[TBL] [Abstract][Full Text] [Related]
2. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
Passman R; Subacius H; Ruo B; Schaechter A; Howard A; Sears SF; Kadish A
Arch Intern Med; 2007 Nov; 167(20):2226-32. PubMed ID: 17998496
[TBL] [Abstract][Full Text] [Related]
3. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
Olshansky B; Poole JE; Johnson G; Anderson J; Hellkamp AS; Packer D; Mark DB; Lee KL; Bardy GH;
J Am Coll Cardiol; 2008 Apr; 51(13):1277-82. PubMed ID: 18371559
[TBL] [Abstract][Full Text] [Related]
4. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.
Goldberger JJ; Subacius H; Schaechter A; Howard A; Berger R; Shalaby A; Levine J; Kadish AH;
J Am Coll Cardiol; 2006 Sep; 48(6):1228-33. PubMed ID: 16979011
[TBL] [Abstract][Full Text] [Related]
5. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
6. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy.
Albert CM; Quigg R; Saba S; Estes NA; Shaechter A; Subacius H; Howard A; Levine J; Kadish A;
Am Heart J; 2008 Aug; 156(2):367-72. PubMed ID: 18657670
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
Corrado D; Calkins H; Link MS; Leoni L; Favale S; Bevilacqua M; Basso C; Ward D; Boriani G; Ricci R; Piccini JP; Dalal D; Santini M; Buja G; Iliceto S; Estes NA; Wichter T; McKenna WJ; Thiene G; Marcus FI
Circulation; 2010 Sep; 122(12):1144-52. PubMed ID: 20823389
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results.
Wathen MS; DeGroot PJ; Sweeney MO; Stark AJ; Otterness MF; Adkisson WO; Canby RC; Khalighi K; Machado C; Rubenstein DS; Volosin KJ;
Circulation; 2004 Oct; 110(17):2591-6. PubMed ID: 15492306
[TBL] [Abstract][Full Text] [Related]
10. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy.
Daubert JP; Winters SL; Subacius H; Berger RD; Ellenbogen KA; Taylor SG; Schaechter A; Howard A; Kadish A;
Pacing Clin Electrophysiol; 2009 Jun; 32(6):755-61. PubMed ID: 19545338
[TBL] [Abstract][Full Text] [Related]
11. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
[TBL] [Abstract][Full Text] [Related]
12. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
[TBL] [Abstract][Full Text] [Related]
14. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
[TBL] [Abstract][Full Text] [Related]
15. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
Costantini O; Hohnloser SH; Kirk MM; Lerman BB; Baker JH; Sethuraman B; Dettmer MM; Rosenbaum DS;
J Am Coll Cardiol; 2009 Feb; 53(6):471-9. PubMed ID: 19195603
[TBL] [Abstract][Full Text] [Related]
16. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
[TBL] [Abstract][Full Text] [Related]
17. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy.
Zecchin M; Di Lenarda A; Proclemer A; Faganello G; Facchin D; Petz E; Sinagra G
Europace; 2004 Sep; 6(5):400-6. PubMed ID: 15294264
[TBL] [Abstract][Full Text] [Related]
18. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
[TBL] [Abstract][Full Text] [Related]
19. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
[TBL] [Abstract][Full Text] [Related]
20. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
